A carregar...
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma
BACKGROUND: A phase II trial was performed to evaluate the efficacy of a dose-dense, 7 days on/7 days off schedule of temozolomide for patients with recurrent high-grade gliomas (HGG). METHODS: Sixty patients with recurrent HGG received temozolomide at 150 mg/m(2)/day on days 1–7 and days 15–21 duri...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4136897/ https://ncbi.nlm.nih.gov/pubmed/24670608 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou044 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|